Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Myosteatosis and Sarcopenic Obesity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Rationale for Mechanism-Driven Multimodal Intervention.

Cancers·2026

Same author

Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer.

Journal for immunotherapy of cancer·2026

Same author

A Prospective Validation of the Decipher Genomic Classifier in Men With Early Localized Prostate Cancer: The VANDAAM Study.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

Nutritional intake of ω-3 fatty acid intake and clinical grade of prostate cancer.

Cancer epidemiology·2025

Same author

Neoadjuvant prostate artery embolization prior to prostate radiation therapy: A single institution experience on the durability of clinical urinary improvement after radiation.

Clinical and translational radiation oncology·2025

Same author

Challenges in Using Deep Neural Networks Across Multiple Readers in Delineating Prostate Gland Anatomy.

Journal of imaging informatics in medicine·2025

Same journal

Bladder Foreign Body of Gastrointestinal Origin: A Case Report and Literature Review.

Archivos espanoles de urologia·2026

Same journal

Real-Time Shear Wave Elastography Combined With MRI-Ultrasound Cognitive Fusion Targeted Biopsy for Repeat Prostate Biopsy.

Archivos espanoles de urologia·2026

Same journal

Evaluating a DeepSeek-Based Case-Based Learning Approach for Teaching the Emergency Management of Urosepsis to Nursing Students.

Archivos espanoles de urologia·2026

Same journal

Association of Fibrosis-Related Gene Expression Profiles in Benign Ureteral Stricture Tissue With Restenosis After Ureteroplasty.

Archivos espanoles de urologia·2026

Same journal

Retrospective Comparison of Transurethral Prostatic Columnar Water Balloon Dilation and Pharmacotherapy for Moderate-to-Severe Benign Prostatic Hyperplasia: Efficacy, Safety and Compliance.

Archivos espanoles de urologia·2026

Same journal

Analysis of the Effect of Stepwise Refined Nursing on the Severity of Ureteral Stent-Related Symptom Clusters After Flexible Ureteroscopic Lithotripsy.

Archivos espanoles de urologia·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 9, 2026

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

Focal Therapy for Prostate Cancer: Available Technologies, Patient Selection, Follow-Up Protocols and Reported

Julio Pow-Sang¹, Gustavo Ruschi Bechara²

¹Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.

Archivos Espanoles De Urologia

|December 3, 2025

Summary

This summary is machine-generated.

Focal therapy (FT) offers a minimally invasive option for intermediate-risk prostate cancer. Challenges in patient selection and varied follow-up protocols need addressing for wider adoption.

Keywords:

focal therapy follow-up protocols localize patient selection prostate cancer

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Related Experiment Videos

Last Updated: Jan 9, 2026

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Area of Science:

Urology
Oncology
Medical Technology

Background:

Focal therapy (FT) for prostate cancer, pioneered with cryoablation, now utilizes diverse energy sources.
Current FT modalities include cryotherapy, irreversible electroporation, HIFU, TULSA, laser, RF ablation, and photodynamic therapy.

Purpose of the Study:

To discuss challenges in patient selection for focal therapy.
To review current focal therapy modalities and post-treatment follow-up strategies.

Main Methods:

Review of existing literature on focal therapy techniques and patient selection criteria.
Analysis of current follow-up protocols involving PSA monitoring, mpMRI, and biopsies.

Main Results:

Focal therapy generally has low morbidity and minimal impact on quality of life.
Long-term oncological outcomes require further investigation.
Heterogeneity in technology, patient selection, and follow-up protocols hinders standardization.

Conclusions:

Focal therapy is a promising option for select intermediate-risk prostate cancer patients.
Standardization of patient selection and follow-up protocols is crucial for establishing FT as a standard treatment.
Further high-level evidence is needed to support widespread adoption.